INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $13.68 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $13.78, a 36.57% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $10.09, a 69.11% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $32.66, a 19.85% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $40.75, a 57.51% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $9.90, a 67.77% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $30.72, a 25.07% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $41.00, a 52.37% decline from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $86.08, a 2.28% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.68 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $13.78 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $9.90 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $9.90 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $9.90 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $10.09 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $30.72 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $30.72 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $31.86 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $32.66 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $41.00 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $41.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $41.00 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $40.75 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $86.08 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $86.08 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $86.08 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $95.90 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $84.16 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $79.17 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $61.07 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $57.94 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $15.04 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $14.20 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $13.59 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | $13.31 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $14.90 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $14.86 10-Q · filed 2019-10-31 | |||
| 2019-06-30 | $14.54 10-Q · filed 2019-08-01 | |||
| 2019-03-31 | $14.13 10-Q · filed 2019-05-02 | |||
| 2018-12-31 | $20.38 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $24.43 10-Q · filed 2018-10-31 | |||
| 2018-06-30 | $24.09 10-Q · filed 2018-08-01 | |||
| 2018-03-31 | $24.44 10-Q · filed 2018-05-01 | |||
| 2017-12-31 | $16.26 10-K · filed 2018-03-14 | |||
| 2017-09-30 | $14.15 10-Q · filed 2017-10-31 | |||
| 2017-06-30 | $13.79 10-Q · filed 2017-08-01 | |||
| 2017-03-31 | $13.71 10-Q · filed 2017-05-02 | |||
| 2016-12-31 | $8.83 10-K · filed 2017-03-14 | |||
| 2016-09-30 | $8.75 10-Q · filed 2016-11-01 | |||
| 2016-06-30 | $8.29 10-Q · filed 2016-08-04 | |||
| 2016-03-31 | $6.83 10-Q · filed 2016-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |